Academic Journal
Highly variable medicines - specific aspects of bioequivalence studies
| Τίτλος: | Highly variable medicines - specific aspects of bioequivalence studies |
|---|---|
| Συγγραφείς: | D. P. Romodanovsky, T. V. Eremenkova, M. A. Dranitsyna, D. V. Goryachev, R. R. Niyazov, E. V. Gavrishina, V. A. Merkulov |
| Πηγή: | Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 4, Pp 5-10 (2018) |
| Στοιχεία εκδότη: | Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018. |
| Έτος έκδοσης: | 2018 |
| Συλλογή: | LCC:Medicine (General) |
| Θεματικοί όροι: | исследования биоэквивалентности, биоэквивалентность, высоковариабельные препараты, bioequivalence studies, bioequivalence, highly variable medicines, Medicine (General), R5-920 |
| Περιγραφή: | At present a specific group of medicines - highly variable medicines - is distinguished based on intraindividual variability data (CVintra > 30%). It is quite difficult to confirm therapeutic equivalence of highly variable medicines by pharmacokinetic bioequivalence studies, and quite a large number of subjects need to be included into the study in order to confirm bioequivalence within standard limits of 80-125%. Variability may be caused by many factors which include physiological and pathophysiological differences in absorption and metabolism processes; factors associated with properties of the active substance and factors associated with the finished product. In general factors impacting variability in bioequivalence studies could be divided into controllable and uncontrollable. The influence of controllable factors can be neutralized by proper performance of the bioequivalence study or proper development of the finished product. The influence of uncontrollable factors cannot be neutralized, and due to these factors medicines can be recognized as highly variable. This article provides a definition of a highly variable medicine, describes reasons for high variability and outlines current regulatory recommendations for and approaches to studying bioequivalence of highly variable medicines, proposes recommendations for designing such studies. |
| Τύπος εγγράφου: | article |
| Περιγραφή αρχείου: | electronic resource |
| Γλώσσα: | Russian |
| ISSN: | 3034-3062 3034-3453 |
| Relation: | https://www.vedomostincesmp.ru/jour/article/view/57; https://doaj.org/toc/3034-3062; https://doaj.org/toc/3034-3453 |
| Σύνδεσμος πρόσβασης: | https://doaj.org/article/4dcfd83ba7e94e3aa7dc6a76b7d27a75 |
| Αριθμός Καταχώρησης: | edsdoj.4dcfd83ba7e94e3aa7dc6a76b7d27a75 |
| Βάση Δεδομένων: | Directory of Open Access Journals |
| ISSN: | 30343062 30343453 |
|---|